Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 4;2020(1):440-449.
doi: 10.1182/hematology.2020000129.

Genomics of MPN progression

Anand A Patel  1 , Olatoyosi Odenike  1
Affiliations
Review

Genomics of MPN progression

Anand A Patel et al. Hematology Am Soc Hematol Educ Program. .

Abstract

The Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs) are a heterogenous group of hematopoietic stem cell diseases characterized by activated JAK/STAT signaling and a variable propensity toward myelofibrotic and leukemic transformation. Acquisition of somatic mutations in addition to the canonical JAK2, MPL, and CALR mutations found in MPNs is an important catalyst in the clonal evolution and progression of these disorders. In recent years, our increasing understanding of the molecular landscape of Ph- MPNs has generated important prognostic information that informs our approach to risk stratification and therapeutic decision-making. This review will focus on the critical impact of genomics on our approach to management of advanced Ph- MPNs.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: O.O. has served on the advisory boards of AbbVie, Celgene, Impact Biomedicines, and Novartis, and has received research support (paid to institution) from AbbVie, Aprea, Astex, Agios, Celgene, CTI Biopharma, Daiichi, Janssen, Kartos, and Oncotherapy Sciences. A.A.P. declares no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Our approach to risk stratification and management of advanced-phase MPNs.
See this image and copyright information in PMC

References

    1. Arber DA, Orazi A, Hasserjian R, et al. . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction appears in Blood. 2016;128(3):462-463]. Blood. 2016;127(20):2391-2405. - PubMed
    1. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680-692. - PMC - PubMed
    1. Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168-2181. - PubMed
    1. Cervantes F, Dupriez B, Pereira A, et al. . New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901. - PubMed
    1. Passamonti F, Cervantes F, Vannucchi AM, et al. . A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708. - PubMed